Beginning Therapeutics, a pharmaceutical company specializing in dermatology, announced today the commercial availability of BenzEFoam ™ (benzoyl peroxide) 5.3% Emollient Foam, the first foam formulation prescription benzoyl peroxide. BenzEFoam ™ Emollient Foam is indicated for the topical treatment of mild to moderate acne. BenzEFoam ™ Emollient Foam is formulated to meet the needs of patients with body acne and provide ideal therapeutic option for them. BenzEFoam ™ is easily passed on extensive areas of the skin of the chest and back where acne body symptoms most often occur. BenzEFoam ™ has demonstrated low rates of skin irritation and dryness in clinical trials. BenzEFoam ™ Emollient Foam is proven very effective in reducing the bacteria causing the acne P. acnes on the back. In a clinical trial, BenzEFoam demonstrated a greater than 100-fold reduction of P. acnes numbers after two weeks of use. "Benzoyl peroxide is a mainstay of acne treatment. Dermatologists have been waiting for a foam formulation of benzoyl peroxide, said Dr. Hilary Baldwin, vice president and associate professor, Department of Dermatology, State University of New York (SUNY), Brooklyn. "We believe that patients prefer and are more consistent application of foam formulations for skin conditions affecting large areas of the body. BenzEFoam ™ is a good treatment option for acne chest and back, and for acne in hairy areas. "
«Nous sommes ravis d'offrir BenzEFoam ™ Emollient mousse comme une option de nouvel organe traitement de l'acné aux dermatologues et de leurs patients», a déclaré Doug Abel, directeur général d'apparition des symptômes Therapeutics. "We believe it is a topical therapy which may improve outcomes in patients with acne appearing on the chest and back because it is effective, well tolerated and easy to spread on these areas more large. " "The development of the first prescription foam emollient benzoyl peroxide is a major achievement for the appearance Therapeutics, said Michael Heffernan, President of Onset Therapeutics. "The clinical results combined with the responses of dermatologists confirm our belief in the value of technology DELEVO Foam ™ and its applicability to many different active ingredients for treating dermatological conditions. The launch of BenzEFoam Emollient Foam ™, our second major product launch this year with Hylatopic ™ Emollient Foam is a testament to our product development team and the broad portfolio of products they have developed. " BenzEFoam Emollient Foam ™ is currently available in all drug wholesalers.
Acne vulgaris is a common skin disease, affecting 40 to 50 million Americans. About 50% of all patients with acne have both front and not the symptoms of facial acne. In the United States last year, more than five million patients with acne sought treatment by a physician, resulting in more than 17 million prescriptions filled, according to data from Verispan and IMS.
BenzEFoam ™ (benzoyl peroxide) 5.3% Emollient Foam is indicated for use in the topical treatment of mild to moderate acne. BenzEFoam Emollient Foam should not be used in patients who have shown hypersensitivity to benzoyl peroxide or any other ingredients in the product. Allergic contact dermatitis and dryness have been reported with topical therapy with benzoyl peroxide. En utilisant ce produit, éviter l'exposition au soleil inutiles et d'utiliser un écran solaire. BenzEFoam, like all products containing benzoyl peroxide, may discolor hair or colored fabrics.
Onset Therapeutics is a specialty pharmaceutical company specializing in the development and commercialization of dermatology products formulated with the Company's innovative technologies formulated exclusive news and unique delivery systems. The company uses its novel DELEVO Foam Technology ™ that is designed to provide increased penetration of active ingredients proven in cosmetically elegant and moisturizing formulations in order to improve patient compliance
«Nous sommes ravis d'offrir BenzEFoam ™ Emollient mousse comme une option de nouvel organe traitement de l'acné aux dermatologues et de leurs patients», a déclaré Doug Abel, directeur général d'apparition des symptômes Therapeutics. "We believe it is a topical therapy which may improve outcomes in patients with acne appearing on the chest and back because it is effective, well tolerated and easy to spread on these areas more large. " "The development of the first prescription foam emollient benzoyl peroxide is a major achievement for the appearance Therapeutics, said Michael Heffernan, President of Onset Therapeutics. "The clinical results combined with the responses of dermatologists confirm our belief in the value of technology DELEVO Foam ™ and its applicability to many different active ingredients for treating dermatological conditions. The launch of BenzEFoam Emollient Foam ™, our second major product launch this year with Hylatopic ™ Emollient Foam is a testament to our product development team and the broad portfolio of products they have developed. " BenzEFoam Emollient Foam ™ is currently available in all drug wholesalers.
Acne vulgaris is a common skin disease, affecting 40 to 50 million Americans. About 50% of all patients with acne have both front and not the symptoms of facial acne. In the United States last year, more than five million patients with acne sought treatment by a physician, resulting in more than 17 million prescriptions filled, according to data from Verispan and IMS.
BenzEFoam ™ (benzoyl peroxide) 5.3% Emollient Foam is indicated for use in the topical treatment of mild to moderate acne. BenzEFoam Emollient Foam should not be used in patients who have shown hypersensitivity to benzoyl peroxide or any other ingredients in the product. Allergic contact dermatitis and dryness have been reported with topical therapy with benzoyl peroxide. En utilisant ce produit, éviter l'exposition au soleil inutiles et d'utiliser un écran solaire. BenzEFoam, like all products containing benzoyl peroxide, may discolor hair or colored fabrics.
Onset Therapeutics is a specialty pharmaceutical company specializing in the development and commercialization of dermatology products formulated with the Company's innovative technologies formulated exclusive news and unique delivery systems. The company uses its novel DELEVO Foam Technology ™ that is designed to provide increased penetration of active ingredients proven in cosmetically elegant and moisturizing formulations in order to improve patient compliance
No comments:
Post a Comment